JP2024542096A5 - - Google Patents
Info
- Publication number
- JP2024542096A5 JP2024542096A5 JP2024526578A JP2024526578A JP2024542096A5 JP 2024542096 A5 JP2024542096 A5 JP 2024542096A5 JP 2024526578 A JP2024526578 A JP 2024526578A JP 2024526578 A JP2024526578 A JP 2024526578A JP 2024542096 A5 JP2024542096 A5 JP 2024542096A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- syndrome
- autoimmune
- fusion protein
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2115803.5 | 2021-11-03 | ||
| GBGB2115803.5A GB202115803D0 (en) | 2021-11-03 | 2021-11-03 | Novel proteins |
| PCT/GB2022/052764 WO2023079278A1 (en) | 2021-11-03 | 2022-11-03 | Novel proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024542096A JP2024542096A (ja) | 2024-11-13 |
| JP2024542096A5 true JP2024542096A5 (cg-RX-API-DMAC7.html) | 2025-10-30 |
Family
ID=78828504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024526578A Pending JP2024542096A (ja) | 2021-11-03 | 2022-11-03 | 新規タンパク質 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250026805A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4426719A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024542096A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240099427A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118369334A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022381844A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3236737A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB202115803D0 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312470A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023079278A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2626300A (en) * | 2022-12-08 | 2024-07-24 | Ducentis Biotherapeutics Ltd | Mutated CD200 proteins and methods of use therof |
| GB202306711D0 (en) * | 2023-05-05 | 2023-06-21 | Ducentis Biotherapeutics Ltd | Novel proteins |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| DE69226871T3 (de) | 1991-06-27 | 2009-09-24 | Bristol-Myers Squibb Co. | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
| EP1171154A2 (en) | 1999-04-13 | 2002-01-16 | Schering Corporation | Uses of mammalian ox2 protein and related reagents |
| WO2008089022A2 (en) | 2007-01-11 | 2008-07-24 | Boehringer Ingelheim International Gmbh | Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts |
| GB201608197D0 (en) * | 2016-05-10 | 2016-06-22 | Ducentis Biotherapeutics Ltd | Novel proteins |
-
2021
- 2021-11-03 GB GBGB2115803.5A patent/GB202115803D0/en not_active Ceased
-
2022
- 2022-11-03 CA CA3236737A patent/CA3236737A1/en active Pending
- 2022-11-03 JP JP2024526578A patent/JP2024542096A/ja active Pending
- 2022-11-03 EP EP22802232.3A patent/EP4426719A1/en active Pending
- 2022-11-03 US US18/707,321 patent/US20250026805A1/en active Pending
- 2022-11-03 IL IL312470A patent/IL312470A/en unknown
- 2022-11-03 AU AU2022381844A patent/AU2022381844A1/en active Pending
- 2022-11-03 KR KR1020247018665A patent/KR20240099427A/ko active Pending
- 2022-11-03 WO PCT/GB2022/052764 patent/WO2023079278A1/en not_active Ceased
- 2022-11-03 CN CN202280081085.3A patent/CN118369334A/zh active Pending